Diversify Advisory Services LLC Purchases Shares of 6,425 Illumina, Inc. $ILMN

Key Points

• Diversify Advisory Services acquired 6,425 Illumina shares worth approximately $1.22 million in the second quarter. Institutional investors and hedge funds collectively own 89.42% of the company.
• Illumina reported quarterly EPS of $1.31, beating estimates by $0.08, while revenue rose 9.4% year over year to $1.16 billion. The company guided to fiscal 2026 EPS of $5.30–$5.40.
• The stock opened at $205, near its 52-week high of $207, but analysts remain divided, resulting in a consensus “Hold” rating and an average price target of $188.40. Insiders have sold more than 1.4 million shares worth approximately $256 million over the past 90 days.

Diversify Advisory Services LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 6,425 shares of the life sciences company's stock, valued at approximately $1,217,000.

Several other hedge funds have also modified their holdings of ILMN. Elyxium Wealth LLC purchased a new stake in Illumina in the fourth quarter valued at approximately $25,000. TD Waterhouse Canada Inc. purchased a new position in Illumina during the fourth quarter worth approximately $26,000. Laurel Wealth Advisors LLC purchased a new position in Illumina during the fourth quarter worth approximately $26,000. Activest Wealth Management boosted its holdings in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 215 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Illumina in the 3rd quarter valued at $32,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Illumina news, SVP Patricia Leckman sold 783 shares of the company's stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares of the company's stock, valued at $3,456,500.81. This represents a 3.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the firm's stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares of the company's stock, valued at $2,311,360. This represents a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,415,351 shares of company stock valued at $255,966,311 in the last 90 days. Company insiders own 2.90% of the company's stock.

Illumina Stock Performance

Illumina stock opened at $205.00 on Thursday. The firm has a market capitalization of $30.95 billion, a PE ratio of 38.25, a price-to-earnings-growth ratio of 2.65 and a beta of 1.45. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00. The stock's 50 day moving average price is $185.90 and its 200 day moving average price is $151.49. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Stifel Nicolaus upped their price objective on Illumina from $155.00 to $225.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Sanford C. Bernstein reissued a "market perform" rating and set a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft cut Illumina to a "hold" rating in a report on Wednesday, August 5th. Canaccord Genuity Group increased their target price on shares of Illumina from $190.00 to $205.00 and gave the stock a "hold" rating in a research report on Monday, August 3rd. Finally, Citigroup raised their price target on shares of Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $188.40.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source